

Nexus AG: Very strong sales and earnings increase in the third quarter 2023

Donaueschingen, 07/11/2023: Nexus AG, one of the leading European suppliers of software solutions in the healthcare sector, was able to increase its sales by 14% and EBT by approx. 33% in the first nine months of 2023. As a result, the continually positive development of sales and earnings of the last years could be continued.

Sales improved from KEUR 150,790 to KEUR 171,266 (+13.6%) in the first nine months 2023. The international share of total business volume was 47.2% (9M-2022: 47.5%) and amounted to KEUR 80,793 compared to KEUR 71,551 (9M-2022). Acquired sales amounting to KEUR 4,790 were consolidated in the reporting period. Organic growth amounted to 10.4%.


New long-term Software-as-a-Service (SaaS) contracts were concluded in 2023 amounting to KEUR 3,750 per year.

The consolidated surplus rose very sharply by 26.1% to KEUR 17,465 (9M-2022: KEUR 13,845), and consolidated earnings before interest and taxes (EBIT) rose by 18.9% to KEUR 22,352 (9M-2022: KEUR 18,794); EBITA increased by 18.9% from KEUR 22,351 (9M-2022) to KEUR 26,583, and EBITDA increased by 13.5% to KEUR 35,454 (9M-2022 KEUR 31,236).

As of 30/09/2023, the company had cash resources at its disposal in the amount of KEUR 98,830 (31/12/2022: KEUR 110,019). Nexus AG had equity capital amounting to KEUR 251,601 as of 30/09/2023 (31/12/2022: KEUR 238,946). Consequently, the equity capital rate is 63.0% (31/12/2022: 69.4%).

The detailed quarterly report can be found on our homepage at: <https://www.nexus-ehealth.com/company/investor-relations>

2012 to 2023 __ EBT (9 months) in KEUR



About Nexus AG

Nexus AG develops and sells software solutions for the international healthcare market. With our core Hospital Information System (NEXUS / HIS) and integrated diagnostic modules (NEXUS / DIS), we have a unique product range, which can cover almost all functional requirements of hospitals, psychiatric institutions, rehabilitation facilities and diagnostic centers within our own product families. The focus of product development is on easy-to-use process support that increases efficiency and safety in patient treatment. NEXUS employs approx. 1,800 people, is present in seven European countries with its own sites and serves customers in an additional 23 countries via certified dealers. Thanks to continuously growing demand for NEXUS products, we have been able to build up a large customer base in recent years and regularly show increases in sales and results.